Who Paid My Doc
Laure Demattia
Obesity Medicine Norman, OK Doctor of Osteopathy
NPI 1235181579 CMS profile 370019
2821 36Th Ave Nw Ste 200, Norman, OK 73072
General payments
$980
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$7,067
Through program year 2024, Laure Demattia of Norman, OK is reported in the CMS Open Payments database as having received $980 across 38 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,067 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 65th percentile of Obesity Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $16 | 1 | |
| 2023 | General | $129 | 5 | |
| 2022 | General | $88 | 2 | |
| 2021 | General | $132 | 6 | |
| 2020 | General | $117 | 6 | |
| 2019 | General | $498 | 18 |
Beside peers
- Laure Demattia
- Obesity Medicine median
- Middle half of Obesity Medicine
- National median
In program year 2025, general payments to Laure Demattia were reported at $0. Among 57 Obesity Medicine profiles paid that year, the median was $178 and the middle half received between $105 and $508.
Show as a table
| Year | Laure Demattia | Obesity Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $498 | $96 | $24–$339 | $163 |
| 2020 | $117 | $53 | $25–$124 | $114 |
| 2021 | $132 | $113 | $40–$251 | $132 |
| 2022 | $88 | $160 | $53–$375 | $149 |
| 2023 | $129 | $125 | $34–$398 | $160 |
| 2024 | $16 | $136 | $81–$475 | $164 |
| 2025 | $0 | $178 | $105–$508 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
590
Drug cost
$361,387
Branded share of claims
64.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 159 | $214,019 | |
| Mounjaro Tirzepatide | Brand | 79 | $111,552 | |
| Wegovy Semaglutide | Brand | 19 | $30,485 | |
| Naltrexone Hcl | Generic | 58 | $2,680 | |
| Omeprazole | Generic | 50 | $789 | |
| Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) | Brand | 29 | $427 | |
| Sucralfate | Generic | 17 | $363 | |
| Ondansetron Hcl | Generic | 20 | $262 | |
| Topiramate | Generic | 47 | $238 | |
| Metformin Hcl Er Metformin Hcl | Brand | 80 | $236 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$11,777
Medicare patients
93
Services billed
155
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 74% | |
| Diabetes | 48% | |
| Depression | 48% | |
| Ischemic heart disease | 29% | |
| COPD | 19% | |
| Atrial fibrillation | 15% | |
| Heart failure | 14% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ONZETRA XSAIL |
|
$8 | — | — |
| CONTRAVE |
|
$8 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
38 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Obesity Medicine in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Obesity Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.